Summary
Read original article →
CBP guidance sets a 29 September clearance deadline for Section 232 tariffs on patented pharmaceuticals, with a 100% ad valorem default and 15% rates for the EU, Japan, Korea and Switzerland. There is no in-transit exception, and imported generics face a 2028 cliff at 100%.